Prostate Specific Antigen Testing after Radical Prostatectomy—Can We Stop at 20 Years?
Abstract
Purpose:
We examined the clinical features and outcomes associated with delayed biochemical recurrence after radical prostatectomy, specifically among men with more than 20 years of followup.
Materials and Methods:
A total of 16,720 men underwent radical prostatectomy and 2,699 experienced biochemical recurrence. We determined predictors of delayed biochemical recurrence as well as metastasis-free and cancer specific survival rates for recurrence at various time points after radical prostatectomy. We performed subset analysis of the 732 men with 20 or more years of recurrence-free followup. Cumulative incidence curves for metastasis and prostate cancer death were calculated and stratified by biochemical recurrence time points.
Results:
Predictors of delayed biochemical recurrence included elevated prostate specific antigen at radical prostatectomy, higher clinical and pathological stage, and positive surgical margins. Delayed biochemical recurrence was associated with favorable cumulative incidence curves for metastasis and prostate cancer death compared to early biochemical recurrence. Among the 732 men with undetectable prostate specific antigen at 20 years biochemical recurrence developed in 17 (2.3%), metastatic disease developed in a single patient and none died of prostate cancer. The actuarial probability of biochemical recurrence among men with undetectable prostate specific antigen at 20 years increased with adverse pathological features.
Conclusions:
Men with delayed biochemical recurrence have favorable clinical features and improved survival. Men with undetectable prostate specific antigen 20 years after radical prostatectomy had a low rate of recurrence and no deaths from prostate cancer. This suggests that 20 years is a reasonable time to discontinue prostate specific antigen testing.
References
- 1 : SEER Cancer Statistics Review, 1975-2011. Bethesda: National Cancer Institute2014. Google Scholar
- 2 : Prostate cancer epidemiology in the United States. World J Urol2012; 30: 195. Google Scholar
- 3 Health, United States, 2014: With Special Feature on Adults Aged 55–64. Hyattsville: National Center for Health Statistics, Centers for Disease Control and Prevention2015. Google Scholar
- 4 : PSA Testing for the Pretreatment Staging and PostTreatment Management of Prostate Cancer: 2013 Revision of 2009 Best Practice Statement. Linthicum: American Urological Association2013. Google Scholar
- 5 : NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw2016; 2016: 111. Google Scholar
- 6 : Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol2000; 164: 101. Link, Google Scholar
- 7 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Google Scholar
- 8 : Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol2005; 23: 7005. Google Scholar
- 9 : A catalog of prostate cancer nomograms. J Urol2001; 165: 1562. Link, Google Scholar
- 10 : Can we stop prostate specific antigen testing 10 years after radical prostatectomy?. J Urol2011; 186: 500. Link, Google Scholar
- 11 : Multiple tests with discrete distributions. Am Stat1997; 51: 3. Google Scholar
- 12 : A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc1999; 94: 496. Google Scholar
- 13 : Deaths: final data for 2014. Natl Vital Stat Rep2016; 65: 1. Google Scholar
- 14 : A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer2008; 112: 1254. Google Scholar
- 15 : Prognostic factors for biochemical recurrence more than ten years after radical prostatectomy. J Urol2016; 195: e716. abstract PD30-11. Link, Google Scholar
- 16 : The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol2003; 170: 1872. Link, Google Scholar
- 17 : Determining when to stop prostate specific antigen monitoring after radical prostatectomy: the role of ultrasensitive prostate specific antigen. J Urol2017; 197: 655. Link, Google Scholar
